We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Medwell Capital Announces that Mimetogen Completes Patient Recruitment in Phase II Clinical Trial for Dry Eye Disease
News

Medwell Capital Announces that Mimetogen Completes Patient Recruitment in Phase II Clinical Trial for Dry Eye Disease

Medwell Capital Announces that Mimetogen Completes Patient Recruitment in Phase II Clinical Trial for Dry Eye Disease
News

Medwell Capital Announces that Mimetogen Completes Patient Recruitment in Phase II Clinical Trial for Dry Eye Disease

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Medwell Capital Announces that Mimetogen Completes Patient Recruitment in Phase II Clinical Trial for Dry Eye Disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Medwell Capital Corp. has announced that Mimetogen Pharmaceuticals completed patient recruitment in its phase II clinical trial of MIM-D3 for dry eye disease. A total of 150 patients have been enrolled in the trial with results expected in the second half of 2011.

Under the terms of the agreement announced on February 25, 2011, Medwell will advance a second tranche of funds pursuant to its $2,000,000 financing commitment.

“We are very pleased that Mimetogen is on track to receive its results in the next few months,” said Kevin Giese, President and CEO of Medwell. “If successful, this drug has the potential to become one of the leaders in the very active ophthalmic space, where there have been over 70 licensing deals completed in the past five years.”

Advertisement